



OPEN

Post-stroke treatment with argon preserved neurons and attenuated microglia/macrophage activation long-termly in a rat model of transient middle cerebral artery occlusion (tMCAO)

Jingjin Liu^{1,7}, Michael Veldeman^{1,2,7}, Anke Höllig^{1,2}, Kay Nolte³, Lisa Liebenstund¹, Antje Willuweit⁴, Karl-Josef Langen^{4,5}, Rolf Rossaint¹ & Mark Coburn⁶✉

In a previous study from our group, argon has shown to significantly attenuate brain injury, reduce brain inflammation and enhance M₂ microglia/macrophage polarization until 7 days after ischemic stroke. However, the long-term effects of argon have not been reported thus far. In the present study, we analyzed the underlying neuroprotective effects and potential mechanisms of argon, up to 30 days after ischemic stroke. Argon administration with a 3 h delay after stroke onset and 1 h after reperfusion demonstrated long-term neuroprotective effect by preserving the neurons at the ischemic boundary zone 30 days after stroke. Furthermore, the excessive microglia/macrophage activation in rat brain was reduced by argon treatment 30 days after ischemic insult. However, long-lasting neurological improvement was not detectable. More sensorimotor functional measures, age- and disease-related models, as well as further histological and molecular biological analyses will be needed to extend the understanding of argon's neuroprotective effects and mechanism of action after ischemic stroke.

Abbreviations

tMCAO	Transient middle cerebral artery occlusion
rCBF	Regional cerebral blood flow
BSA	Bovine serum albumin
NeuN	Neuronal nuclear antigen
Iba1	Ionized calcium binding adaptor molecule 1
ROIs	Regions of interests
IBZ	Ischemic boundary zone
IRS	Immunoreactive score
ANOVA	Analysis of variance
MAP	Mean arterial blood pressure
HR	Heart rate
CNS	Central nervous system

Stroke has become one of the most common causes of death as well as a leading cause of major disability worldwide¹, of which 87% are ischemic in nature². So far, timely reperfusion achieved by intravenous tissue

¹Department of Anesthesiology, University Hospital RWTH Aachen, Aachen, Germany. ²Department of Neurosurgery, University Hospital RWTH Aachen, Aachen, Germany. ³Department of Neuropathology, University RWTH Aachen, Aachen, Germany. ⁴Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Jülich, Jülich, Germany. ⁵Department of Nuclear Medicine, RWTH University Hospital, Aachen, Germany. ⁶Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. ⁷These authors contributed equally: Jingjin Liu and Michael Veldeman. ✉email: mark.coburn@ukbonn.de




Figure 1. Flowchart of animal enrollment and experimental design.

plasminogen activator (tPA) or endovascular thrombectomy remains the only effective intervention for acute ischemic stroke patients^{3,4}. However, patients who are eligible for the treatment are quite limited^{5,6}. Access to the treatment is also limited by resources⁷. Likewise, the intervention has considerable shortcomings, such as symptomatic hemorrhagic transformation, which is a devastating complication of intravenous thrombolysis treatment and is associated with high mortality^{8,9}. Moreover, although reperfusion within a certain time window can reduce infarct size and improve clinical outcome, cerebral reperfusion injury can occur and exacerbate the brain injury^{10,11}. Taken together, stroke as a major public health issue requires urgent development of new effective therapeutic strategies.

In recent years, argon has proven to be an effective neuroprotectant in an array of in vivo and in vitro models^{7,11–19}. Argon is inexpensive and easy to transport. It does not have anesthetic properties at the concentrations used, therefore would not confound neurological assessment if used in a pre-hospital setting. Furthermore, ventilation with argon appears to be safe in pigs and preliminary human trials²⁰. In the context of cerebral ischemia injury, argon has shown to be beneficial after both transient and permanent ischemic stroke insults^{7,11,12}. Meanwhile, evidence from animal studies indicates that argon could be neuroprotective not only in a pre-hospital setting but also during later treatment in stroke unit. In a recent study, we demonstrated that argon administration with a 3 h delay after stroke onset and 1 h after reperfusion significantly alleviated neurological deficit within the first week and alleviated neuronal damage in the ischemic boundary zone 7 days after stroke. Moreover, argon reduced the excessive microglia/macrophage activation and promoted the switch of microglia/macrophage polarization towards the anti-inflammatory M₂ phenotype⁷. However, the long-term effects of argon after cerebral ischemia injury have not been reported so far. In the present study, we further investigate the underlying neuroprotective effects of argon up to 30 days after stroke insult in accordance with the Stroke Therapy Academic Industry Roundtable recommendations²¹. Meanwhile, the long-term influence of argon on microglia/macrophage activation and polarization will also be explored.

Results

All animals survived until being euthanized. Thus, the data from a total of 20 animals (n = 7 for tMCAO Ar and tMCAO N₂ groups, n = 3 for sham Ar and sham N₂ groups) underwent final statistical analyses for left and right rCBF, MAP, HR, blood gas analysis, baseline body weight, neuroscore, infarct volume measurement and immunohistochemical analysis. The number of animals enrolled in each group as well as the subsequent outcome measures were listed in Fig. 1.

Monitoring, blood gas analysis and body weight. The regional cerebral blood flow measurement of the left middle cerebral artery showed an expected reduction from baseline level during the tMCAO procedure. At the time point of tMCAO induction, the rCBF values dropped to 22.7% ± 11.9% for tMCAO Ar group and 30.1% ± 9.3% for tMCAO N₂ group, respectively. In the reperfusion period, the values returned to baseline level. In the meantime, the regional cerebral blood flow measurement of the right middle cerebral artery exhibited steady values during the whole surgical procedure, which ruled out the possibility of subarachnoid hemorrhage. Neither courses of left rCBF nor right rCBF showed significant difference between tMCAO Ar and tMCAO N₂ groups (p = 0.87 for left rCBF and p = 0.55 for right rCBF) (Fig. 2a,b). Neither courses of MAP nor courses of HR showed significant difference between tMCAO Ar and tMCAO N₂ groups (p = 0.39 for MAP and p = 0.94 for HR) (Fig. 2c,d). At time points before tMCAO, after tMCAO induction, after onset of reperfusion and after the beginning of gas application (50% Vol N₂/50% Vol O₂ for tMCAO N₂ group, 50% Vol Argon/50% Vol O₂ for




Figure 2. Left regional cerebral blood flow (rCBF) (a) and right rCBF (b) as percentage of baseline value; mean arterial blood pressure (MAP) in mmHg (c); heart rate (HR) in beats per minute (d). The courses of left rCBF, right rCBF, MAP and HR did not differ between tMCAO Ar and tMCAO N₂ groups. B = baseline, 5 min after tail artery catheter insertion, time point 0 = tMCAO induction, time point 120 = start of reperfusion, time point 180 = the beginning of gas application (50% Vol N₂/50% Vol O₂ for tMCAO N₂ group, 50% Vol Argon/50% Vol O₂ for tMCAO Ar group). Data were extracted in 10 min intervals. Results were represented as mean $\pm$ SD, $n = 7$ for tMCAO Ar and tMCAO N₂ groups.

tMCAO Ar group), none of the parameters of blood gas analysis (pH, pCO₂, pO₂, cK⁺ and cNa⁺) differed statistically between tMCAO Ar and tMCAO N₂ groups ($p = 0.06$ for pH, $p = 0.81$ for pCO₂, $p = 0.80$ for pO₂, $p = 0.82$ for cK⁺ and $p = 0.37$ for cNa⁺) (Table 1). The baseline body weights of rats were comparable in tMCAO Ar and tMCAO N₂ groups (336.1 ± 19.8 g v.s. 358.5 ± 33.2 g, $p = 0.42$).

	Time 1	Time 2	Time 3	Time 4
pH				
tMCAO N ₂	7.32 (0.08)	7.35 (0.07)	7.33 (0.04)	7.38 (0.03)
tMCAO Ar	7.42 (0.10)	7.42 (0.04)	7.38 (0.04)	7.42 (0.05)
pCO₂				
tMCAO N ₂	52.9 (7.1)	45.8 (6.0)	51.1 (4.1)	39.9 (5.1)
tMCAO Ar	48.2 (1.6)	45.2 (5.5)	49.1 (5.3)	45.5 (6.0)
pO₂				
tMCAO N ₂	155.0 (13.6)	133.0 (8.7)	176.0 (14.3)	201.7 (6.8)
tMCAO Ar	150.0 (6.2)	163.0 (14.7)	183.7 (8.1)	163.0 (12.9)
cK⁺				
tMCAO N ₂	5.4 (0.5)	5.4 (0.7)	5.0 (0.6)	4.5 (1.0)
tMCAO Ar	5.1 (0.1)	5.1 (0.6)	5.1 (0.5)	5.1 (0.3)
cNa⁺				
tMCAO N ₂	136.3 (4.0)	132.7 (16.3)	133.3 (11.9)	142.7 (5.5)
tMCAO Ar	134.3 (9.1)	139.3 (3.1)	141.3 (1.2)	142.0 (4.4)

Table 1. Blood gas analysis. Results were represented as mean (SD), n = 7 for tMCAO Ar and tMCAO N₂ groups. Time 1 = baseline, 5 min after tail artery catheter insertion, Time 2 = after tMCAO induction, Time 3 = after onset of reperfusion, Time 4 = after the beginning of gas application (50% Vol N₂/50% Vol O₂ for tMCAO N₂ group, 50% Vol Argon/50% Vol O₂ for tMCAO Ar group).




Figure 3. Quantification of brain infarct volume 30 days after reperfusion. Results were represented as mean $\pm$ SD, n = 7 for tMCAO Ar and tMCAO N₂ groups.

Argon preserved neurons at the ischemic boundary zone long-termly after tMCAO. To determine whether argon has neuroprotective effects after ischemic stroke, firstly, we measured the infarct volume 30 days after reperfusion. Quantitative analysis of the percentage of brain hemispheric loss, which reflected the originally infarcted tissue, did not show significant difference between tMCAO Ar and tMCAO N₂ groups ($p = 0.41$) (Fig. 3).

We analyzed subsequently the effect of argon on the survival of neurons at IBZ area 30 days after reperfusion using NeuN immunostaining. NeuN staining is robust and is widely used to detect neurons⁷. Quantitative analysis revealed that the relative numbers of NeuN positive cells in the ROIs of tMCAO N₂ group were significantly fewer than the values of Sham N₂ group ($p = 0.00017$ for cortex and $p = 0.0029$ for subcortex). In contrast, the relative numbers of NeuN positive cells in the ROIs of tMCAO Ar group did not differ from those of Sham N₂ group ($p = 0.51$ for cortex and $p = 0.63$ for subcortex). When compared to tMCAO N₂ group, the relative numbers of NeuN positive cells in the ROIs of tMCAO Ar group were significantly higher ($p = 0.030$ for cortex and $p = 0.030$ for subcortex). (Fig. 4).

Argon suppressed microglia/macrophage activation long-termly after tMCAO. Previous studies revealed that the microglia/macrophage activation is fully developed hours to days after ischemic stroke onset^{22–24} and declines thereafter. A similar tendency was also observed in our studies. The intensity of microglia/macrophage activation 30 days after reperfusion reduced dramatically compared to 7 days after reperfusion⁷.




Figure 4. Neuronal nuclear antigen (NeuN) staining of rat brain samples. Representative images of NeuN immunohistochemistry in cortex and subcortex of ischemic boundary zone (IBZ) 30 days after reperfusion (**a**); relative number of NeuN positive cells detected in cortex (**b**) and subcortex (**c**) of IBZ; representative image of regions of interests (ROIs) for NeuN quantification (**d**). Significance was indicated with *** $p < 0.001$, ** $p < 0.01$ and * $p < 0.05$. Argon treatment significantly increased the relative numbers of NeuN positive cells in cortex and subcortex of IBZ compared to tMCAO N₂ group ($p = 0.030$ for cortex and $p = 0.030$ for subcortex). Results were represented as mean $\pm$ SD, $n = 7$ for tMCAO Ar and tMCAO N₂ groups, $n = 3$ for sham Ar and sham N₂ groups.

Notably, while three functionally and morphologically different types of microglia/macrophages were observed 7 days after ischemic stroke, namely the classical resting microglia within the non-affected areas, the intermediately activated “stellate” microglia at the IBZ and the highly activated “amoeboid” microglia/macrophages at the ischemic core⁷, only resting microglia and “stellate” microglia were found in rat brain 30 days after ischemia onset. The “amoeboid” microglia/macrophages were no longer visible as the damaged tissue was taken up by cells and a cavity formed within the ischemic core. Quantitative analysis using IRS demonstrated that argon treatment significantly suppressed microglia/macrophage activation in rat central nervous system (CNS) 30 days after reperfusion ($p < 0.0001$) (Fig. 5).

Argon did not alleviate neurological deficit long-termly after tMCAO. The 6-point neuroscore on d29 did not reveal any significant difference between the four groups ($p = 0.57$) (Fig. 6).

Discussion

In a previous study, we found that argon treatment 3 h after stroke onset and 1 h after reperfusion improved neurological performance during the first week after ischemic stroke, preserved the neurons of the ischemic boundary zone and alleviated the excessive microglia/macrophage activation in rat CNS 7 days after the insult⁷. In the present study, it was further demonstrated that the same treatment strategy protected the neurons and reduced the microglia/macrophage activation at the IBZ 30 days after ischemic stroke. However, the neuroscore assessed on d29 was incapable to detect any difference between different experimental settings. The findings of long-lasting neuroprotective and anti-inflammatory effects of argon after ischemic stroke strengthened the role of argon as a new promising therapeutic agent in stroke treatment. However, additional studies are needed to elucidate to what extent and under which circumstances argon will be beneficial after ischemic stroke insult.

The long-lasting neuroprotective and anti-inflammatory effects of argon after ischemic stroke. In recent years, the neuroprotective effects of argon in context of cerebral ischemia injury have been reported in several studies using different experimental stroke models and with different therapeutic regimens^{7,11,12}. When administered for 1 h until reperfusion with a 1 h delay after tMCAO induction, argon has demonstrated to reduce the infarct volume and relieve the composite adverse outcome 24 h after reperfusion¹². Moreover, using the same therapeutic strategy as in the present study, namely with a 3 h delay after stroke onset




Figure 5. Microglia/macrophage activation with ionized calcium binding adaptor molecule 1 (Iba1) immunohistochemistry in rat brain 30 days after reperfusion. Representative images of resting microglia in sham groups and activated microglia/macrophages at IBZ in tMCAO groups 30 days after reperfusion (a); representative image of overall microglia/macrophage activation in rat brain sample of tMCAO N₂ group 30 days after reperfusion (b); quantitative analysis of microglia/macrophage activation using immunoreactive score (IRS) 30 days after reperfusion (c). Significance was indicated with **** $p < 0.0001$. Treatment of argon significantly suppressed the microglia/macrophage activation in rat brain ($p < 0.0001$). Results were represented as mean $\pm$ SD, $n = 7$ for tMCAO Ar and tMCAO N₂ groups.




Figure 6. 6-point neuroscore tested on d29 after reperfusion. Results were represented as mean $\pm$ SD, $n = 7$ for tMCAO Ar and tMCAO N₂ groups, $n = 3$ for sham Ar and sham N₂ groups.

and 1 h after reperfusion, argon has shown to significantly ameliorate neurological deficit during the first week after stroke and to promote neuronal survival in the ischemic boundary zone 7 days after reperfusion⁷. In the present study, it was further proven that argon could preserve neurons at the ischemic boundary zone until 30 days after reperfusion. However, no influence of argon on the infarct volume was detected.

Although statistical analysis didn't reveal any difference of the course of left rCBF between tMCAO Ar and tMCAO N₂ groups in the present study, the degree of rCBF reduction during the period of middle cerebral artery occlusion and the degree of rCBF recovery after reperfusion were not identical between two groups. Animals in tMCAO Ar group had a relative severer decrease of cerebral blood flow and a relative higher degree of reperfusion. These variations may have impact on the histological and functional outcomes in the present study.

Interestingly, Ma and colleagues¹¹ found that argon inhalation for 24 h immediately after onset of permanent focal cerebral ischemia could provide neuroprotection and improve neurological outcome 7 days after the insult; however, when argon treatment was delayed for 2 h after permanent stroke induction or until after reperfusion,

neurological outcome was improved, but no reduction of infarct size was detected. Similar finding with respect to the inconsistency of infarct size and functional outcome was also revealed in our previous study⁷, in which argon was administered 3 h after transient ischemic stroke onset. These findings indicate that an early start of treatment is essential to accomplish optimal protection, therefore, should be strived to achieve. On the other hand, one should be aware that the correlation between infarct size and functional impairments is at best moderate and the value of histological lesion size as a clinically relevant outcome predictor is still controversial^{7,11,21,25–28}. The severity of neurological impairments also depends on the actual location of the lesion, whereas size may be less important^{11,29}. Besides, the functional and/or structural reorganization of the remaining brain plays important roles after ischemic stroke too. In particular, the peri-infarct tissue is an important target for neurorepair and neuroprotective therapies^{7,30}. The long-lasting neuroprotective and anti-inflammatory effects of argon at the ischemic boundary zone may be a reasonable explanation for the functional improvement after delayed argon treatment.

Inflammation is considered as a key contributor to the pathophysiology of ischemic stroke^{31,32} and microglia activation is the first step of inflammatory response in the CNS^{32–34}. Accumulating evidence suggests that activated microglia after ischemic stroke insult might be a therapeutic target to limit neuronal cell death and improve clinical outcome^{32,35,36}. In the present study, along with the long-lasting neuroprotective effect of argon after ischemic stroke, it was revealed that argon treatment could long-termly alleviate the excessive microglia/macrophage activation.

Excessively activated microglia/macrophages following ischemic stroke could be detrimental to neuronal survival and repair by producing proinflammatory cytokines and cytotoxic substances, influencing astrocyte activation and reactive gliosis, and affecting neurogenesis^{32,37,38}. Further studies are needed to elucidate the detailed mechanisms involved in argon's neuroprotective and anti-inflammatory effects after ischemic stroke.

Strikingly, accumulating evidence reveals that microglia/macrophages may have a dual role in ischemic stroke^{32,37,39}. Despite the traditional deleterious role, studies have shown that microglia could also contribute to tissue repair and remodeling by clearing up debris and producing anti-inflammatory cytokines and growth factors, and could be beneficial for the functional recovery after cerebral ischemia^{32,40–42}. Microglia were demonstrated to be supportive of neurogenesis under certain circumstances³². The distinct role of microglia/macrophages after brain injury may be attributed to different polarization under different cellular contexts and pathological stages^{32,37,39}. Therefore, exclusively suppressing microglia activation may not be a suitable therapeutic strategy for ischemic brain injury, as the beneficial role of microglia/macrophages might be compromised. Therapeutic approaches should aim at modulating the activation of microglia and drive microglia polarization to a protective phenotype^{32,39}. Given that argon could long-termly suppress the microglia/macrophage activation and meanwhile promote the switch of microglia/macrophage polarization towards the anti-inflammatory M₂ phenotype⁷, it may serve as a new promising therapeutic approach in ischemic stroke treatment.

Functional outcomes. *Wistar* rats were chosen as the experimental subject in the present study because studies showed that different rat strains display different behavioral and histological outcomes after experimental ischemia^{43–45} and that tMCAO induces larger ischemic lesions and formation of edema in *Wistar* rats⁴⁵. It is surprising that no statistical difference of the 6-point neuroscore was found between animals who received tMCAO and the sham animals, although a massive decrease of the rCBF value was achieved at the tMCAO induction (the left rCBF values decreased to 23.8% for tMCAO Ar group and 30.7% for tMCAO N₂ group) and a considerable hemispheric loss was demonstrated 30 days after stroke (24.9% for tMCAO Ar group and 19.5% for tMCAO N₂ group). Due to the spontaneous recovery after stroke event, a statistical significance of the functional test was undetectable between argon and placebo treatment.

Spontaneous recovery after stroke has been reported to be common for many functional outcome measures^{21,46,47}. A sociodemographic study with regard to the prevalence of poststroke cognitive impairment revealed an overall prevalence ratio of long-lasting cognitive impairment to be 22%⁴⁸. Moreover, in most of the animal studies, cerebral ischemia was induced in young healthy animals, in which the spontaneous recovery may be more likely. Whereas stroke in humans occurs as a result of the natural progression of underlying diseases or risk factors, such as aging, hypertension and diabetes⁴⁹. Suenaga et al.⁵⁰ demonstrated that aged rodents exhibit significantly severer long-term sensorimotor and cognitive deficits combined with significantly larger brain infarct size. In humans, it has also been stated that the cognitive impairment rate in stroke survivors was strongly associated with age⁴⁸. Taken together, considering the potential possibility of spontaneous recovery after stroke in different functional outcomes, a battery of neurological and behavioral assessments would be beneficial to draw a panorama of the functional protective effect of potential treatments^{47,51}. Related to the present study, more behavioral measures with respect to different aspects of sensorimotor function, such as Rotarod, Cylinder test, Catwalk test and Forelimb placing, are needed in future^{46,47}. Further, studies performed in age-related models or disease-related models may be of great interest and would extend the understanding of argon's neuroprotective effect after stroke.

Limitations and prospective. The design of a 3 h-delayed argon administration after stroke onset is more relevant to clinical practice³ and would provide valuable data to guide the development of new therapeutic strategies for patients. In addition, continuous perioperative monitoring, especially the bilateral rCBF assessment, assured experimental quality and eliminate falsification of the experimental results by including undesired pathologies⁵¹. For the first time, to the best of our knowledge, the long-term effects of argon after ischemic stroke were explored. The findings with regard to the long-lasting neuroprotective and anti-inflammatory effects of argon after stroke could deepen the understanding of the treatment strategy. However, several limitations exist in the present study. Further studies are needed to confirm and extend the findings of the present study.

Although appropriate sample size was calculated based on the determined primary outcome, namely the 6-point neuroscore on d29, considering the possibility of spontaneous recovery, a much larger sample size is highly advisable in order to detect the potential benefit of the treatment. Age-related and disease-related models should be taken into account in future studies. Meanwhile, the functional tests being used should be chosen carefully and a battery of neurological and behavioral assessments would be beneficial to reveal the potential protective property of the therapeutic regimen. Computer-assisted and automated systems may offer an additional objective evaluation^{51,52}.

Adequate observation time points for assessing long-term functional performance are needed to form an overall perspective of the potential treatment effect. On the one hand, the functional performance after stroke may be fluctuant^{7,47,53}. On the other hand, given that in adulthood every day of a laboratory rat is approximately equivalent to 34.8 human days⁵⁴, an improvement even within the first two or three weeks after experimental ischemia onset would be of great importance for clinical practice²¹.

Except for microglia/macrophage activation and polarization, more functional and/or structural alterations, including astrocyte reactivity, neurogenesis, blood–brain barrier permeability, cerebral vasoconstriction, synaptic plasticity, axonal remodeling and angiogenesis at the ischemic boundary zone, even within the non-affected hemisphere, are of importance to uncover the panorama of argon's neuroprotective effects after ischemic stroke⁷. Furthermore, molecular pathways which are involved in argon's neuroprotective and anti-inflammatory effects need to be further elucidated.

50% Vol argon was used in the present study based on a previous in vitro study from our group¹⁴, which demonstrated that 50% argon offers a maximum neuroprotective effect compared to 25% and 74% argon. Importantly, human data from a small cohort of healthy volunteers (n = 4) showed that exposure to 50% argon is safe for up to 6 days³⁵. Besides, from a clinically relevant consideration, 50% of argon allows a higher inspiratory oxygen concentration for patients in demand¹⁴. However, studies are needed to further assess the optimal concentration, timing and duration of argon application in in-vivo experimental stroke models.

Current evidence shows significant protective effect of argon after both transient and permanent ischemic stroke insults^{7,11,12}. However, detailed experimental setups differ between studies. Considering the heterogeneity of human stroke, studies including both disease subgroups and concerning the similarities and differences in their protective mechanisms would be of great interest.

Conclusions

In the present study, argon administration with a 3 h delay after stroke onset and 1 h after reperfusion demonstrated long-term neuroprotective and anti-inflammatory effects in the rat brain. However, long-lasting neurological improvement was not detectable. More sensorimotor functional measures, age- and disease-related models, as well as further histological and molecular biological analyses will be needed to extend the understanding of argon's neuroprotective effects and mechanisms after ischemic stroke. Given that argon is easy to apply (via face mask) and is lack of apparent toxicity^{11,20}, it is neuroprotective and suppresses microglia/macrophage activation while promotes the switch of microglia/macrophage polarization towards the anti-inflammatory M₂ phenotype⁷, it may serve as a new promising therapeutic approach for ischemic stroke patients.

Materials and methods

Animals and treatment groups. Animals were housed and assigned to groups as described before⁷. A total of 32 male *Wistar* rats (body weight 300–400 g; Charles River, Sulzfeld, Germany) were housed for at least 1 week before surgery with free access to food and water on a 12-h light/dark cycle. A parallel design was applied to the present study with the allocation ratio of 1:1. Animals were randomly assigned by drawing lots. Animals were sequentially numbered to ensure the allocation concealment. The assignments were enclosed in sealed envelopes and were not accessible to the researchers who were responsible for animal care as well as behavioral and histological assessments.

tMCAO procedure. The tMCAO procedure was performed as described before⁷. Anesthesia was induced by intraperitoneal injection of midazolam (2 mg/kg) (Ratiopharm, Ulm, Germany), medetomidine (0.15 mg/kg) (Zoetis, Florham Park, NJ), and fentanyl (0.005 mg/kg) (Rotexmedica, Trittau, Germany), and maintained by hourly intraperitoneal application of 0.03–0.05 ml of this anesthetics combination. Animals were intubated and ventilated with 50% Vol N₂/50% Vol O₂. Blood gas analysis was conducted for each animal to insure proper ventilation, at: 5 min after tail artery catheter insertion, after tMCAO induction, after onset of reperfusion and after the beginning of gas application. A polyethylene catheter was inserted into the tail artery to measure blood pressure and to take blood samples for blood gas analysis. Electrocardiographic needle electrodes were placed for continuous heart rate monitoring.

Briefly, a silicone-coated 4–0 nylon monofilament was introduced via left common carotid artery into the internal carotid artery, and advanced until resistance was felt and the cerebral blood flow measurement of the left side showed a sufficient drop. Reperfusion was accomplished by withdrawal of the filament 2 h after tMCAO induction. One hour after reperfusion, animals received either 50% Vol Argon/50% Vol O₂ (Air Liquide, Paris, France) or 50% Vol N₂/50% Vol O₂ for 1 h. During the entire surgical procedure and treatment, body temperature was maintained at 37–37.5 °C through a feedback-controlled heating pad (Physitemp Instruments, Clifton, NJ). Analgesic treatment (Flunixin, 1 mg/kg s.c.) was carried out daily from the day of surgery till d3.

Assessment of regional cerebral blood flow (rCBF). The rCBF assessment was performed as described before⁷. The rCBF assessment over the left and right middle cerebral artery was performed by laser Doppler flowmeter (Moor Instruments, Axminster, Devon, United Kingdom) during the entire tMCAO procedure and

treatment to insure appropriate middle cerebral artery occlusion and reperfusion. The laser Doppler probes were placed on the animal's skull approximately 1 mm posterior to the bregma and 5 mm lateral to the midline. Baseline measurement was taken 5 min after tail artery catheter insertion.

6-Point neuroscore. Neurological function was examined by a blinded investigator using the 6-point neuroscore as reported previously^{7,12}. The neuroscore was evaluated on d29. The 6-point neuroscore was graded in six levels from 0 to 5: 5 = normal motor function, no neurologic deficit; 4 = flexion of torso and contralateral forelimb when lifted by the tail; 3 = decreased resistance to lateral push without circling; 2 = circling to the contralateral side against resistance when tugged by the tail on a flat surface; 1 = circling spontaneously to the contralateral side; 0 = no spontaneous motor activity, loss of walking or righting reflex.

Tissue sampling. The tissue sampling was performed as described before⁷. Rats were euthanized on d30 by terminal anesthesia. After that, brains were removed and immediately fixed in 4% paraformaldehyde. Forty-eight hours later, rat brains were sectioned into 2 mm coronal blocks, and in total, six blocks per animal were embedded in paraffin. A 2- μ m section from the anterior side of each block was collected for hematoxylin–eosin staining and the following infarct volume measurement. Sections from the 4th block (1 mm to -1 mm in the coronal plane from Bregma) were used for other stainings (see below).

Infarct volume measurement. The infarct volume measurement was performed as described before⁷ and was modified to fit the present experimental design. Sections were stained with routine hematoxylin–eosin and were visualized and photographed with the EVOS FL Auto Imaging System (Life Technologies, Carlsbad, California, United States) using a 10 $\times$ objective. Images were analyzed using ImageJ 1.46r (<https://imagej.nih.gov/ij>). The infarct volume was calculated by an indirect method of subtracting the non-lesioned volume of the ipsilateral hemisphere from the non-lesioned volume of the contralateral hemisphere, and was normalized to the volume of the contralateral hemisphere of the same section.

Immunohistochemistry. The immunohistochemical stainings and subsequent analyses were performed as described before⁷ and were modified to fit the present experimental design. 2- μ m sections were cut from paraffin-embedded brain blocks and were placed on silane-coated slides. Sections were dewaxed, rehydrated and heated in citrate buffer for antigen retrieval. Nonspecific binding was blocked by incubating sections in phosphate buffered saline containing either 1% normal goat serum or 1% bovine serum albumin (BSA). The following primary antibodies were used: mouse anti-neuronal nuclear antigen (NeuN) (1:200; Merck Millipore, Billerica, MA) and rabbit anti-ionized calcium binding adaptor molecule 1 (Iba1) (1:500; Wako Chemicals, Neuss, Germany). Stained sections were photographed with the Axioplan microscope (ZEISS, Oberkochen, Germany) at 40 $\times$ objective using Zen 2 blue edition (<https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html#>). For NeuN immunostaining, regions of interests (ROIs) were set to the cortex and subcortex of ischemic boundary zone (IBZ). Nuclei were counted in two images from cortex and three images from subcortex of IBZ. Values were expressed as relative values in relation to the number of neurons counted in images collected from identical locations in the contralateral hemisphere of the same slice. For Iba1 immunostaining, three images of IBZ were used for analysis. Quantification of the results was performed by using the immunoreactive score (IRS) according to Remmele and Stegner, which considers both the staining intensity and the number of stained cells⁵⁶.

Quantification and statistical analysis. The statistical analysis was performed as described before⁷ and was modified to fit the present experimental design. The 6-point neuroscore on d29 was determined as the primary outcome. Sample size was calculated based on our previous study⁷. The calculation was performed using nQuery Advisor + nTerim 4.0 (Statistical Solutions, Saugus, MA, USA). The portal used for one-way analysis of variance (ANOVA) data was selected. The number of groups was set to 4. An average difference of 0.7 between groups was expected, and the standard deviation was assumed to be 1.2. The significance was set to 5% and the statistical power to 80%. Thus, the minimum sample size was defined as $n = 7$. All data were expressed as mean $\pm$ SD. Normality of the data was tested by Shapiro–Wilk test and homogeneity of variance was tested by Levene's test. Independent t-Test was used to perform the comparison between two groups (tMCAO Ar v.s. tMCAO N₂ group). One-Way ANOVA was applied to assess comparisons between four groups, if necessary, Bonferroni post hoc test was used for following multiple comparisons. Courses of left and right rCBF, mean arterial blood pressure (MAP) and heart rate (HR), and blood gas analysis were compared using repeated measures ANOVA. All calculations were performed using SPSS 23.0 (IBM, Chicago, IL). $p < 0.05$ was considered statistically significant.

Ethics approval and consent to participate. The research protocol and animal care procedures of this study were approved by the State Office for Nature, Environment and Consumer Protection (AZ 84–02.04.2013. A418, Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen). All experiments were performed in accordance with the German legislation governing animal studies (Tierschutzgesetz, Tierschutz-Versuchstierverordnung) and the ARRIVE guidelines 2.0⁵⁷.

Data availability

All data generated or analysed during this study are included in this published article.

Received: 30 May 2021; Accepted: 24 December 2021

Published online: 13 January 2022

References

- Donnan, G. A., Fisher, M., Macleod, M. & Davis, S. M. Stroke. *Lancet* **371**, 1612–1623. [https://doi.org/10.1016/S0140-6736\(08\)60694-7](https://doi.org/10.1016/S0140-6736(08)60694-7) (2008).
- Writing Group, M. *et al.* Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation* **133**, e38–360. doi:<https://doi.org/10.1161/CIR.0000000000000350> (2016).
- Powers, W. J. *et al.* Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. *Stroke* **50**, e344–e418. <https://doi.org/10.1161/STR.0000000000000211> (2019).
- Powers, W. J. *et al.* 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* **46**, 3020–3035. <https://doi.org/10.1161/STR.0000000000000074> (2015).
- Kanazawa, M., Takahashi, T., Nishizawa, M. & Shimohata, T. Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke. *J. Atheroscler. Thromb.* **24**, 240–253. <https://doi.org/10.5551/jat.RV16006> (2017).
- Goyal, M. *et al.* Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* **387**, 1723–1731. [https://doi.org/10.1016/S0140-6736\(16\)00163-X](https://doi.org/10.1016/S0140-6736(16)00163-X) (2016).
- Liu, J. *et al.* Post-stroke treatment with argon attenuated brain injury, reduced brain inflammation and enhanced M2 microglia/macrophage polarization: a randomized controlled animal study. *Crit. Care* **23**, 198. <https://doi.org/10.1186/s13054-019-2493-7> (2019).
- Yaghi, S. *et al.* Treatment and outcome of hemorrhagic transformation after intravenous Alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American heart association/American stroke association. *Stroke; a journal of cerebral circulation* **48**, e343–e361. <https://doi.org/10.1161/STR.0000000000000152> (2017).
- Seet, R. C. & Rabinstein, A. A. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. *Cerebrovasc. Dis.* **34**, 106–114. <https://doi.org/10.1159/000339675> (2012).
- Pan, J., Konstas, A. A., Bateman, B., Ortolano, G. A. & Pile-Spellman, J. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. *Neuroradiology* **49**, 93–102. <https://doi.org/10.1007/s00234-006-0183-z> (2007).
- Ma, S. *et al.* Argon inhalation for 24 hours after onset of permanent focal cerebral ischemia in rats provides neuroprotection and improves neurologic outcome. *Crit. Care Med.* **47**, e693–e699. <https://doi.org/10.1097/CCM.0000000000003809> (2019).
- Ryang, Y. M. *et al.* Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats. *Crit. Care Med.* **39**, 1448–1453. <https://doi.org/10.1097/CCM.0b013e31821209be> (2011).
- Hollig, A. *et al.* Beneficial properties of argon after experimental subarachnoid hemorrhage: early treatment reduces mortality and influences hippocampal protein expression. *Crit. Care Med.* **44**, e520–529. <https://doi.org/10.1097/CCM.0000000000001561> (2016).
- Loetscher, P. D. *et al.* Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. *Crit. Care* **13**, R206. <https://doi.org/10.1186/cc8214> (2009).
- Bruckner, A. *et al.* Argon reduces neurohistopathological damage and preserves functional recovery after cardiac arrest in rats. *Br. J. Anaesth.* **110**(Suppl 1), i106–112. <https://doi.org/10.1093/bja/aes509> (2013).
- Bruckner, A. *et al.* Dose dependent neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by K(ATP)-channel opening. *Resuscitation* **85**, 826–832. <https://doi.org/10.1016/j.resuscitation.2014.02.014> (2014).
- Zhuang, L. *et al.* The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. *Crit. Care Med.* **40**, 1724–1730. <https://doi.org/10.1097/CCM.0b013e3182452164> (2012).
- Zhao, H. *et al.* Argon protects against hypoxic-ischemic brain injury in neonatal rats through activation of nuclear factor (erythroid-derived 2)-like 2. *Oncotarget* <https://doi.org/10.18632/oncotarget.8241> (2016).
- Ulbrich, F. *et al.* Argon mediates protection by Interleukin-8 suppression via a TLR2/TLR4/STAT3/NF-kappaB pathway in a model of apoptosis in neuroblastoma cells in-vitro and following ischemia-reperfusion injury in rat retina in-vivo. *J. Neurochem.* <https://doi.org/10.1111/jnc.13662> (2016).
- Gardner, A. J. & Menon, D. K. Moving to human trials for argon neuroprotection in neurological injury: a narrative review. *Br. J. Anaesth.* **120**, 453–468. <https://doi.org/10.1016/j.bja.2017.10.017> (2018).
- Stroke Therapy Academic Industry, R. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke* **30**, 2752–2758 (1999).
- Lee, J. H. *et al.* Regulation of therapeutic hypothermia on inflammatory cytokines, microglia polarization, migration and functional recovery after ischemic stroke in mice. *Neurobiol. Dis.* **96**, 248–260. <https://doi.org/10.1016/j.nbd.2016.09.013> (2016).
- Lambertsen, K. L., Finsen, B. & Clausen, B. H. Post-stroke inflammation-target or tool for therapy?. *Acta Neuropathol.* <https://doi.org/10.1007/s00401-018-1930-z> (2018).
- Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y. & Rosenberg, G. A. Neuroinflammation: friend and foe for ischemic stroke. *J. Neuroinflammation* **16**, 142. <https://doi.org/10.1186/s12974-019-1516-2> (2019).
- Ahnstedt, H. *et al.* U0126 attenuates cerebral vasoconstriction and improves long-term neurologic outcome after stroke in female rats. *J. Cereb. Blood Flow Metab.* **35**, 454–460. <https://doi.org/10.1038/jcbfm.2014.217> (2015).
- Lopez-Valdes, H. E. *et al.* Memantine enhances recovery from stroke. *Stroke* **45**, 2093–2100. <https://doi.org/10.1161/STROKEAHA.113.004476> (2014).
- Ortega, F. J., Jolkonen, J., Mahy, N. & Rodriguez, M. J. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. *J. Cereb. Blood Flow Metab.* **33**, 356–364. <https://doi.org/10.1038/jcbfm.2012.166> (2013).
- Shehadah, A. *et al.* Efficacy of single and multiple injections of human umbilical tissue-derived cells following experimental stroke in rats. *PLoS ONE* **8**, e54083. <https://doi.org/10.1371/journal.pone.0054083> (2013).
- Zhang, L. *et al.* Diabetes mellitus impairs cognitive function in middle-aged rats and neurological recovery in middle-aged rats after stroke. *Stroke* **47**, 2112–2118. <https://doi.org/10.1161/STROKEAHA.115.012578> (2016).
- Ramos-Cabrer, P., Campos, F., Sobrino, T. & Castillo, J. Targeting the ischemic penumbra. *Stroke* **42**, S7–11. <https://doi.org/10.1161/STROKEAHA.110.596684> (2011).
- Moskowitz, M. A., Lo, E. H. & Iadecola, C. The science of stroke: mechanisms in search of treatments. *Neuron* **67**, 181–198. <https://doi.org/10.1016/j.neuron.2010.07.002> (2010).
- Ma, Y., Wang, J., Wang, Y. & Yang, G. Y. The biphasic function of microglia in ischemic stroke. *Prog. Neurobiol.* <https://doi.org/10.1016/j.pneurobio.2016.01.005> (2016).
- Iadecola, C. & Anrather, J. The immunology of stroke: from mechanisms to translation. *Nat. Med.* **17**, 796–808. <https://doi.org/10.1038/nm.2399> (2011).

34. Jin, R., Yang, G. & Li, G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. *J. Leukoc. Biol.* **87**, 779–789. <https://doi.org/10.1189/jlb.1109766> (2010).
35. Price, C. J. *et al.* Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. *Stroke* **37**, 1749–1753. <https://doi.org/10.1161/01.STR.0000226980.95389.0b> (2006).
36. Thiel, A. & Heiss, W. D. Imaging of microglia activation in stroke. *Stroke* **42**, 507–512. <https://doi.org/10.1161/STROKEAHA.110.598821> (2011).
37. Xiong, X. Y., Liu, L. & Yang, Q. W. Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. *Prog. Neurobiol.* **142**, 23–44. <https://doi.org/10.1016/j.pneurobio.2016.05.001> (2016).
38. Xu, S., Lu, J., Shao, A., Zhang, J. H. & Zhang, J. Glial cells: role of the immune response in ischemic stroke. *Front. Immunol.* **11**, 294. <https://doi.org/10.3389/fimmu.2020.00294> (2020).
39. Hu, X. *et al.* Microglial and macrophage polarization—new prospects for brain repair. *Nat. Rev. Neurol.* **11**, 56–64. <https://doi.org/10.1038/nrneurol.2014.207> (2015).
40. Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. *Nat. Rev. Immunol.* **11**, 762–774. <https://doi.org/10.1038/nri3070> (2011).
41. Neumann, H., Kotter, M. R. & Franklin, R. J. Debris clearance by microglia: an essential link between degeneration and regeneration. *Brain J. Neurol.* **132**, 288–295. <https://doi.org/10.1093/brain/awn109> (2009).
42. Neumann, J. *et al.* Microglia provide neuroprotection after ischemia. *FASEB J.* **20**, 714–716. <https://doi.org/10.1096/fj.05-4882fje> (2006).
43. Bardutzky, J. *et al.* Differences in ischemic lesion evolution in different rat strains using diffusion and perfusion imaging. *Stroke* **36**, 2000–2005. <https://doi.org/10.1161/01.STR.0000177486.85508.4d> (2005).
44. Oliff, H. S., Weber, E., Eilon, G. & Marek, P. The role of strain/vendor differences on the outcome of focal ischemia induced by intraluminal middle cerebral artery occlusion in the rat. *Brain Res.* **675**, 20–26. [https://doi.org/10.1016/0006-8993\(95\)00033-m](https://doi.org/10.1016/0006-8993(95)00033-m) (1995).
45. Walberer, M. *et al.* Experimental stroke: ischaemic lesion volume and oedema formation differ among rat strains (a comparison between Wistar and Sprague-Dawley rats using MRI). *Lab. Anim.* **40**, 1–8. <https://doi.org/10.1258/002367706775404426> (2006).
46. Yousef, S. *et al.* Long-term behavioral deficits and recovery after transient ischemia in middle-aged rats: Effects of behavioral testing. *Restor. Neurol. Neurosci.* **33**, 251–261. <https://doi.org/10.3233/RNN-140450> (2015).
47. Encarnacion, A. *et al.* Long-term behavioral assessment of function in an experimental model for ischemic stroke. *J. Neurosci. Methods* **196**, 247–257. <https://doi.org/10.1016/j.jneumeth.2011.01.010> (2011).
48. Douiri, A., Rudd, A. G. & Wolfe, C. D. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995–2010. *Stroke* **44**, 138–145. <https://doi.org/10.1161/STROKEAHA.112.670844> (2013).
49. Fisher, M. *et al.* Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke* **40**, 2244–2250. <https://doi.org/10.1161/STROKEAHA.108.541128> (2009).
50. Suenaga, J. *et al.* White matter injury and microglia/macrophage polarization are strongly linked with age-related long-term deficits in neurological function after stroke. *Exp. Neurol.* **272**, 109–119. <https://doi.org/10.1016/j.expneurol.2015.03.021> (2015).
51. Liebenstund, L. *et al.* Predicting experimental success: a retrospective case-control study using the rat intraluminal thread model of stroke. *Disease models & mechanisms* <https://doi.org/10.1242/dmm.044651> (2020).
52. Balkaya, M. G., Trueman, R. C., Boltze, J., Corbett, D. & Jolkkonen, J. Behavioral outcome measures to improve experimental stroke research. *Behav. Brain Res.* **352**, 161–171. <https://doi.org/10.1016/j.bbr.2017.07.039> (2018).
53. Zausinger, S., Scholler, K., Plesnila, N. & Schmid-Elsaesser, R. Combination drug therapy and mild hypothermia after transient focal cerebral ischemia in rats. *Stroke* **34**, 2246–2251. <https://doi.org/10.1161/01.STR.0000083622.65684.21> (2003).
54. Sengupta, P. The laboratory rat: relating its age with human's. *Int. J. Prev. Med.* **4**, 624–630 (2013).
55. Antonov, A. A. & Ershova, T. A. [Retention of the skill to perform adaptive bio-control of bioelectrical activity synchronization in the human brain cortex in an argon-nitrogen-oxygen atmosphere with various oxygen content]. *Aviakosmicheskaja i ekologicheskaja meditsina = Aerospace and environmental medicine* **43**, 27–31 (2009).
56. Remmele, W. & Stegner, H. E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. *Pathologe* **8**, 138–140 (1987).
57. Percie du Sert, N. *et al.* The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. *PLoS biology* **18**, e3000410. <https://doi.org/10.1371/journal.pbio.3000410> (2020).

Acknowledgements

We thank Rosmarie Blaumeiser-Debarry and Birgit Nellessen for their technical assistance.

Author contributions

J.L. acquired data, analyzed and interpreted data as well as drafted the manuscript. M.V. acquired and analyzed data, evaluated and edited the manuscript. A.H. helped with conception of study and data interpretation. K.N. helped with histological analysis. L.L., A.W., K.J.L. and R.R. helped to evaluate and edit the manuscript. M.C. conceived and designed the study, supervised development of work, helped with data interpretation and manuscript evaluation, and acts as corresponding author. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. This study was supported by the Deutsche Forschungsgemeinschaft CO 799/9–1. J.L. received grant support from Overseas Study Program of Guangzhou Elite Project.

Competing interests

AH lectured for Air Liquid Santé International. RR and MC consulted and lectured for Baxter Healthcare and Air Liquide. JL, MV, KN, LL, AW, and KJL declared that they do not have competing interest.

Additional information

Correspondence and requests for materials should be addressed to M.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022